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Bone repair access of BoneCeramicTM 
in 5-mm defects: study on rat calvaria
Objective: The aim of this study was to evaluate the osteoconductive 
potential of BoneCeramicTM on bone healing in rat calvaria 5-mm defects. 
Material and Methods: A 5-mm calvaria bone defect was induced in three 
groups and the defect was not filled with biomaterial [Clot Group (CG)], 
autogenous bone (AG), or Bone Ceramic Group (BCG). Animals were 
euthanized after 14 or 28 days and the bone tissue within the central area 
of the bone defect was evaluated. Results were compared using ANOVA 
and Tukey test (p<0.05). Immunohistochemistry was performed using 
primary antibodies against osteocalcin, RUNX-2, TRAP, VEGF proteins, and 
3-dimensional images of the defects in μCT were obtained to calculate bone 
mineral density (BMD). Results: In BCG, the defect was completely filled with 
biomaterial and new bone formation, which was statistically superior to that 
in the GC group, at both time-points (p<0.001 for 14 days; p=0.002 for 28 
days). TRAP protein showed weak, RUNX-2 showed a greater immunolabeling 
when compared with other groups, VEGF showed moderate immunostaining, 
while osteocalcin was present at all time-points analyzed. The μCT images 
showed filling defect by BCG (BMD= 1337 HU at 28 days). Conclusion: 
Therefore, the biomaterial tested was found to be favorable to fill bone 
defects for the reporting period analyzed.
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Introduction
Functional recovery of the jaws using dental 
implants requires a minimum thickness and height of 
ridges1,5,15. Several factors culminate in the absence 
of alveolar bone, which then becomes a limiting factor 
for implant placement. This usually occurs in patients 
who have suffered dentoalveolar trauma, traumatic 
tooth extractions, dental congenital absence, or other 
diseases involving the maxilla and mandible2,9,17.
The current trend is to develop and use biomaterials 
that accelerate or at least allow normal and complete 
repair of bone defects, thus reducing postoperative 
failure rate7,22. The objective of tissue engineering is 
to generate an osteoconductive biomaterial that is 
conducive to bone healing or even superior to bone 
grafts17.
Synthetic bone substitutes with osteoconductive 
property, such as calcium phosphate-based ceramic 
biomaterials, have been investigated10,11,20. Recently, 
Miramond, et al.14 (2014) showed that isolated biphasic 
calcium phosphate has osteoinductive potential 
when used within subcutaneous tissue. The physical 
properties of biomaterials vary as per their surface 
area or the format (block or particle), porosity (dense, 
micro-, or macroporous) and crystallinity (crystalline 
or amorphous). On the other hand, chemical properties 
are related to the chemical composition of the material 
such as calcium/phosphate molar ratio, the level of 
elemental impurities, and ionic substitution in the 
atomic structure24.
Straumann© BoneCeramicTM (BC) is a 100% 
synthetic bone substitute with morphology to stimulate 
the formation of vital bone. It has 90% porosity 
index, with interconnected pores with 100 to 500 
microns diameter and is composed of biphasic calcium 
phosphate, with 60% hydroxyapatite (HA) and 40% 
β-tricalcium phosphate. The mechanical stability of 
the increased volume is maintained due to the slow 
resorption of HA, which prevents excessive resorption, 
according to the manufacturer instructions. Studies 
by Daculsi, et al.4 (2003), Cordaro, et al.3 (2008), 
Frenken, et al.6 (2010), Mardas, et al.12 (2011), 
and Wang, et al.23 (2014) showed that BC is a bone 
substitute with osteoconductive properties, favorable 
for repair of bone defects, with similar results for 
amount of mineralized bone when compared with 
inorganic bovine bone (Bio-Oss®). However, there 
was a greater amount of soft tissue component and 
different features of resorption for the BC group3, 
therefore, these authors have recommended further 
studies to confirm the results.
The aim of this study was to evaluate the 
osteoconductive potential of HA granules and 
β-tricalcium phosphate (BoneCeramic – Straumann®) 
in the repair of 5-mm defects in rat calvaria, 
using histometry, immunohistochemistry, and 
microtomographic analysis, at 14 and 28 days, 
compared with defect not filled with biomaterial 
(negative control) or autogenous bone graft (positive 
control).
We propose the null hypothesis that the bone area 
of newly formed bone defects filled with autogenous 
bone or BC will not show a statistical difference.
Material and methods 
Experimental design
This research was approved by the Ethics Committee 
on Animal Experiments (process 2012/01097). A 
total of 56 adult (3–4-month-old) male rats (Rattus 
norvegicus albinus, Wistar), weighing approximately 
200 to 300 g, were used. The animals were divided 
into three groups (n=8 each) and euthanized at one 
of the two time-points: 14 and 28 days after surgery. 
They were kept in cages and fed with balanced feed 
(NUVILAB, Curitiba, PR, Brazil) containing 1.4% Ca 
and 0.8% P and provided water ad libitum in the our 
institution.
A bone defect (5 mm) was induced in the calvaria 
of each animal as follows:
•Clot Group (CG, n=16): The bone defect was not 
filled with some biomaterial (the defect remain empty 
until clot stabilization);
•Autogenous Bone Group (AG, n=16): The 5-mm 
bone defect was filled with autogenous bone (collected 
from the calvaria of the same animal). After the defect 
was made, the bone was particulate and used to fill 
the defect;
•Bone Ceramic Group (BCG, n=24): The 5-mm bone 
defect was filled with alloplastic bone (Straumann). 
For this group, eight additional animals were operated 
upon and euthanized after 42 days to verify the long-
term behavior of this group.
Experimental surgery
The animals were subjected to preoperative 
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12-hour fasting and sedated by intramuscular 
administration with Coopazine® (10 mg/kg xylazyne; 
Coopers Ltd., Brazil) and Vetaset® (75 mg/kg ketamine 
hydrochloride; Saúde Animal Ltd., Fort Dodge, IA, 
USA). Trichotomy was carried out in the region of 
the calvaria, antisepsis with polyvinylpyrrolidone 
iodine degerming (PVPI 10% Riodeine degerming, 
Rioquímica, São José do Rio Preto, SP, Brazil), 
associated with topical PVPI (PVPI 10% Riodeine, 
Rioquímica, São Jose do Rio Preto, SP, Brazil) and 
affixed barren areas.
A U-shaped incision was made in the occipitofrontal 
sense, based toward the posterior region with a no. 15 
blade (Feather Industries Ltd., Tokyo, Japan) mounted 
on a no. 3 scalpel handle (Hu-Friedy, Germany) and 
the total detachment of the flap with peeler Molt 
type (Hu-Friedy, Germany). Using a trephine drill aid 
(3i Implant Innovations, Inc., Palm Beach Gardens, 
USA) coupled in low rotation speed under abundant 
irrigation with sodium chloride solution 0.9% (Darrow, 
Rio de Janeiro, RJ, Brazil), a 5-mm surgical defect was 
made at the central portion of the calvaria involving the 
sagittal suture, maintaining the integrity of the dura21. 
According to the proposed treatments, the defects 
were not filled with biomaterial (n=16), autogenous 
bone (n=16), or synthetic bone – Straumann Bone 
Ceramic (n=24).
To finish the procedure, the soft tissues (including 
the periosteum) were carefully repositioned and 
sutured at the surface with a resorbable wire 
(polylactic acid – Vycril 4.0, Ethicon, Johnson Prod, São 
José dos Campos, SP, Brazil) and in deeper areas using 
monofilament plan (Nylon 5.0, Mononylon , Ethicon, 
Johnson Prod., São José dos Campos, SP, Brazil) with 
the most points externally interrupted.
During the immediate postoperative period, each 
animal received a single intramuscular dose of 0.2 
mL penicillin G benzathine (small-size veterinary 
pentabiotic, Fort Dodge Saúde Animal Ltda., Campinas, 
SP, Brazil). The animals were kept in individual cages 
throughout the experiment with food and water 
supplied ad libitum.
The animals were postoperatively euthanized at 14 
or 28 days with an overdose of anesthetic (thiopental 
sodium, 150 mg/kg). In the BCG group, eight animals 
were postoperatively euthanized at 42 days.
Calvaria of rats were removed and fixed in 
10% formaldehyde solution for 48 hours, washed 
in running water for 24 hours, decalcified in 20% 
ethylenediaminetetraacetic acid for 6 weeks followed 
by alcohol dehydration, and cleared in xylene. 
Subsequently, the calvariae were longitudinally cut 
in half, separating the bone defects. The specimens 
obtained were embedded in paraffin and cut 
using a microtome into 6-μm-thick sections and 
placed on slides. Some slides were stained with 
hematoxylin and eosin (HE) while others were used 
for immunohistochemical analysis.
Prior to performing the analyses, samples were 
coded in such a way that only the supervisor was 
aware of the group corresponding to each slide. 
Subsequently, the examiner performed the analyses 
in a blinded manner.
Histometric analysis
After staining the slides in HE (Merck & Co., 
Inc.), measurements were performed using a 
×1.6 magnifying glass (LeicaR DMLB, Heerbrugg, 
Switzerland) and a lens with ×20 magnification (Leica 
Microsystems Aristoplan, Leitz, Benshein, Germany). 
These were coupled to an image-capturing camera 
(LeicaR DC 300F microsystems ltd, Heerbrugg, 
Switzerland) and connected to a computer with 
software to analyze the scanned images (Image J, 
Image Processing and Analysis Software, Ontario, 
Canada). These images were stored in JPEG format 
for subsequent analysis and projected onto the 
screen of a Samsung monitor (SyncMaster 3NE, 15 
inches). Initially, the program was calibrated by the 
“set scale” tool, from the ruler image photographed 
under a microscope with ×1.6 magnification by the 
magnifying glass and ×20 by the lens. Thus, all images 
held according to the pattern of capture groups in the 
magnification of ×1.6 and ×20.
Hence, the images of the groups were analyzed 
using the Image J program. Using the “hands free” 
tools, the area of newly formed bone tissue was 
selected from the osteotomized bone stumps, as well 
as the area of connective tissue, biomaterial, and blood 
clot, while the program estimated the size in µm2.
Statistical analysis
Statistical analysis was performed using Sigma Plot 
software 12.3 (San Jose, CA, USA) as per standards 
from previous studies8,11,16. The comparative analysis 
of biomaterials was performed using 2-criteria variance 
analysis, after having performed the test of normality 
(Kolmogorov-Smirnov) and the equal variance test. 
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Specific analysis for BCG (14, 28, and 42 days) was 
performed using analysis of variance (ANOVA) to 
a criterion25 after having performed the normality 
test (Kolmogorov-Smirnov) and equal variance test. 
Analysis of the time periods was performed using 
paired t-test8,16 and the normality test (Shapiro-Wilk) 
was used. For all analyses, the Tukey test was used as 
a post-test. We adopted a significance level of p<0.05.
Immunohistochemical analysis
The immunohistochemistry analysis included the 
following steps: inhibition of endogenous peroxidase 
activity with hydrogen peroxide, antigen retrieval with 
citrate buffer at 60°C for 20 minutes, and blocking of 
unspecific reactions with skim milk and bovine albumin 
during incubation of antibodies.
We used primary antibodies (dilution 1:100) 
against transcription factor 2 Runt-related (RUNX-2), 
tartrate-resistant acid phosphatase (TRAP), vascular 
endothelial growth factor (VEGF), and osteocalcin (OC) 
(Santa Cruz Biotechnology), biotinylated secondary 
antibody, with 1:200 dilution (Pierce Biotechnology), 
the Streptavidin Biotin amplifier (Dako), and 
diaminobenzidine (Dako) as a chromogen. At the 
end of the reactions, counter-staining with Harris 
hematoxylin was performed. Negative controls were 
used (by omission of the primary antibodies) to avoid 
false positives.
For the analysis, an optical microscope with 
increased objective ×40 Leica Microsystems Aristoplan 
(Leitz, Benshein, Germany) coupled to an image-
capture camera (Leica DFC 300FX, Leica Microsystems, 
Heerbrugg, Switzerland) and connected to a 
microcomputer with a software capable of analyzing 
scanned images (Leica Camera Software Box, Leica 
Imaging Manager -IM50 Demo Software) was used. A 
total of three images were obtained from each strip for 
analysis: the two edges and the center of the defect. 
For comparison of immunostaining intensity between 
the experimental groups, scores were created in which 
immunostaining was classified on a scale of 0 to 3 
(absent – 0, mild – 1, moderate – 2, and intense – 
3). The immunostaining was represented by average 
percentage of labeling for each protein evaluated. 
Thus, score 1 showed about 25% of immunolabeling; 
score 2: 50%, and score 3: 75% of immunolabeling. 
These patterns are based on the studies of Pedrosa, 
et al.18 (2009) and Ramalho-Ferreira, et al.19 (2016).
Microtomographic analysis
After euthanasia (at 14 and 28 days for all 
groups and after 42 days for the additional group 
BC) and removal of the calvaria, they were fixed in 
paraformaldehyde and, prior to laboratory processing 
to obtain the histological slides, two samples of each 
group and time period were subjected to the evaluation 
through a computer-assisted microtomograph (μCT; 
Bruker micro CT, Skyscan, S), using sections of 9 
µm in thickness (60 Kv and 165 μA), with aluminum 
(0.5 mm) filter and 0.6-mm rotation step, pixel size 
of 9.92 μm and acquisition time of 23 minutes. The 
images obtained by the projection of X-rays in the 
samples were stored and reconstituted determining 
the area of interest by NRecon software (SkyScan 
2011, Version 1.6.6.0), with smoothing of 1 artifact 
rings correction of 5, beam hardening correction of 
20% and image conversion varied from 0.0 to 0.15. 
The pattern of new bone formation was evaluated 
by 3-dimensional images obtained by Datavier and 
CTvox software (Skyscan, Be). Bone mineral density 
(BMD) was assessed by the CTan software (Skycan, 
S) in Hounsfield Units (HU), by measuring the mineral 
density at the central area of the defect in the different 
experimental periods (14, 28, and 42 days).
Results 
Histological/histometric analysis
The site of the bone defect originally treated 
with BC was filled by a conglomerate of biomaterial 
and newly formed bone. BC remnants were visible 
and were in close contact with the bone tissue. 
Furthermore, we observed similar results in the GA 
group (Figure 1). The Tukey post-test indicated that, 
at 14 days, the autogenous bone formed more bone 
compared with the clot (p<0.001), and similar results 
were observed in the BC versus (vs.) clot (p<0.001) 
groups. At 28 days, the autologous bone showed a 
greater area of bone formation when compared with 
the clot (p<0.001) and the BC group (p=0.002). Thus, 
BCG was more favorable for the formation of bone 
tissue when compared with the clot (p<0.001). Clot 
was the most unfavorable group, as shown in Figure 
2. Regarding the time for each biomaterial, it was 
observed that there was an increase in autogenous 
bone tissue formation from 14 to 28 days (p=0.002), 
but the other groups showed no statistically significant 
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Figure 1- Histological images of experimental groups (CG at 14 days and CG at 28 days; AG at 14 days and AG at 28 days; BCG at 14 
days, 28 days, 42 days. (1.6x magnification – Loupe). Different signs were used to identify the type of tissue: *=Connective tissue; += 
Neoformed bone; #=BoneCeramic particles; -=Autograft particles
Figure 2- Neoformed bone tissue at 14 and 28 days
Figure 3- Graphic box-plot showing BCG. Bone and connective tissue at 14, 28 and 42 days
2018;26:e201605315/12
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difference for the clot (p=0.845) and BC groups 
(p=0.511). A specific analysis of the bone ceramic 
group indicated that there was no statistically 
significant difference in bone formation at 14 vs. 28 
days (p=0.511), 14 vs. 42 days (p=0.319), and 28 
vs. 42 days (p=1.000) (Figure 3).
Defects that were not filled with biomaterial (GC) 
had a thin connective tissue closing the bone defect. 
The BC group may have favored the formation of 
bone, which was observed in the samples at 14, 28, 
and 42 days, and neogenesis was similar in the three 
periods. As expected, no substantial bone formation 
was observed in the group clot defects, while the 
particulate autogenous bone group resulted in the 
closure of the original defects (Figure 1). 
At 14 days, BCG showed increased formation 
of connective tissue compared with the autologous 
group (p<0.001) and the clot group showed increased 
Figure 4- Neoformed connective tissue at 14 and 28 days
Figure 5- Osteocalcin immunostaining (OC) at 14 days for the experimental groups (CG: light; AG: moderate; BCG: moderate). At 28 days 
(CG: light; AG: moderate; BCG: moderate). Immunolabeling indicated by red arrows
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Figure 6- RUNX-2 immunostaining at 14 days for the experimental groups (CG: light; AG: moderate; BCG: moderate) and at 28 days (CG: 
light; AG: moderate; BCG: light). Immunolabeling indicated by red arrows
Figure 7- TRAP immunostaining at 14 days for the experimental groups (CG: light; AG: moderate; BCG: light) and at 28 days (CG: light; 
AG: light; BCG: moderate). Immunolabeling indicated by red arrows
2018;26:e201605317/12
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formation of connective tissue compared with the 
autologous group (p<0.001). However, there was no 
significant difference in the comparison of BCG and 
clot (p=0922) groups, power test α=1.0. At 28 days, 
BCG showed the highest formation of connective 
tissue compared with the autologous and clot groups 
(p<0.001) (Figure 4).
Immunohistochemistry
In the analysis of immunoblots, positive markings 
were observed on the osteoblasts and extracellular 
matrix of the three evaluate experimental groups. 
Specifically at 28 days, in areas with bone formation, 
osteocalcin labeling was observed near to the 
mineralized bone matrix, showing the greater maturity 
of these specimens. Light immunostaining was 
observed for the control group at 14 and 28 days. For 
AG and BC groups, in both periods, immunostaining 
was moderate (Figure 5), but it is important to note 
that the AG has a great quantity of positive labeling 
in the mineralized bone matrix.
RUNX-2: In the three experimental groups, we 
observed positive staining of this transcription factor 
in very young pre-osteoblasts, osteoblasts and in 
some cases, osteocytes, in particular in the AG and BC 
groups. However, at 28 days, particularly in the clot 
and BC groups, there was a drop in positive staining 
of this factor in the cells of osteoblast lineage. This 
protein was lightly expressed in BCG (14 and 28 days), 
whereas in AG it was moderately expressed at 14 and 
28 days. As for the BCG at 14 days it was observed 
as moderate, but at 28 days, there was a decrease in 
the immunostaining (light) (Figure 6).
TRAP: At 14 and 28 days for the control group, 
the immunostaining of this protein was light. For AG, 
it was moderately marked at 14 days and there was 
decreased expression at 28 days (light). This was in 
contrast to BCG, which showed slight immunostaining 
at 14 days and moderate at 28 days (Figure 7).
VEGF: An important positive staining for this 
growth factor was observed in the three experimental 
groups, particularly the CG and BC groups, for which 
this protein was moderately expressed in both periods 
(14 and 28 days) analyzed. On the other hand, AG was 
expressed lightly at 14 days and moderate (especially 
close to mineralized matrix) at 28 days (Figure 8).
Figure 8- VEGF immunostaining at 14 days for the experimental groups (CG: moderate; AG: light; BCG: moderate) and at 28 days (CG: 
moderate; AG: moderate; BCG: moderate). Immunolabeling indicated by red arrows
2018;26:e201605318/12
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Microtomography
Images obtained by μCT showed the defect filled 
by BC (14, 28, and 42 days) and AG (14 and 28 days). 
The AG group showed full compatibility bone formation 
after 28 days; however, the defect was not fully filled 
in the CG as expected (Figure 9). The average BMD 
for the CG, AG, and BCG was 498, 850, and 935 HU 
at 14 days and 485, 1797, and 1337 HU at 28 days, 
respectively. Moreover, the BMD for BCG was 1554 HU 
at 42 days (Figure 10).
Discussion
We rejected the null hypothesis that the newly 
formed bone area within the bone defect filled with 
autogenous bone or BC would not show a statistical 
difference, considering that for all analyzed periods 
the autologous bone showed a greater extent of 
bone formation compared with the other biomaterials 
(p<0.05). However, BC was satisfactorily responsible 
for filling bone defects, when compared with the 
control group (p<0.05), with mean BMD values similar 
to GA.
The results obtained in our study indicate that the 
tested biomaterial (BCG) with the clot was favorable 
for recovery of the bone defect compared with filling 
Figure 9- Images obtained by μCT of CG, AG, and BCG (14, 28 and 42 days). Bone neoformation was observed with total filling of defect 
at 28 days in GA. BCG promoted filling of defect with the biomaterial until the 42-day period
Figure 10- BMD average data obtained by μCT of CG, AG, and BCG (14, 28 and 42 days)
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with the clot alone. However, even though the bone 
quantity observed in BCG was lesser in extent than 
the autograft, this bone quantity was maintained 
in all of the evaluated periods, being important to 
fill the calvaria defect. This was probably due to HA 
(60%) in the composition of BoneCeramic®, which has 
very low absorption. Thus, the material remained at 
the insertion site, filling the defect until 42 days, in 
contrast to the autogenous bone graft, which closed 
the defect with mineralized bone at 28 days.
As BCG showed a small amount of newly formed 
bone with full closure of the defect at 28 days when 
compared with the positive control group, it was 
noteworthy to determine BC results at a later time-
point. Considering that this group presented important 
labeling of RUNX2, that is, immunoblotting referring to 
pre-osteoblastic cells that may be indirectly related to 
a possible tendency of late bone formation. Therefore, 
the 42-day BCG analysis was conducted.
Similarly as performed in our study, Takuti, et 
al.21 (2014) also evaluated the bone repair of BC 
in 5-mm size defects, but in defects with 8 mm of 
diameter and rabbits’ calvaria. These authors found 
greater percentage of newly bone formed to BC 
groups (78.06%) when compared with xenograft 
(Bio-Oss: 57.76%; Endobon: 58.42%). A surprising 
statistical interaction with control group (clot: 77.8%) 
was observed. Furthermore, these data were not 
supported by representative histological images, which 
did not seem to show the same results observed by 
histometric analysis. For this reason, our study was 
important to show some differences to BC behavior in a 
lower defect (5 mm) and another animal experimental 
model (rats).
Regarding osteoconductive property of the 
biomaterials, Luvizuto, et al.11 (2011) employed 
β-tricalcium phosphate (βTCP 100%, Cerasorb®) and 
other biomaterials (polylactic and polyglycolic acid gel 
and calcium phosphate cement) for filling 5-mm bone 
defects in the calvaria of rats at day 45 post-surgery. 
These biomaterials were used alone or supplemented 
with 5 μg bone morphogenetic protein (BMP-2) and 
compared with defects filled with autogenous bone. 
The authors observed that TCP alone promoted bone 
formation more efficiently compared with autografts 
and that BMP-2 supplementation was not required for 
filling bone defects. TCP was resorbed and allowed 
formation of mature bone tissue, closing the surgical 
defect. Thus, the results of these studies show that 
the presence of HA, with low absorption filled the 
bone defect at the last time-point in this study, with a 
lower rate of bone formation. Clinically, Daculsi, et al.4 
(1999) observed a resorption rate of about 50% with 
BC used as a graft in the maxillary sinus membrane at 
1 year post-operation, confirming the slow resorption 
of the material.
This is not to say that the preservation of the 
material, without full closure of the defect with 
neoformed bone is unfavorable for bone repair; 
however, only one may ask about the quality of 
this bone to support dental implants, first regarding 
the primary stability of the implant and then 
regarding osseointegration. Results obtained with 
microtomographic evaluation were encouraging in this 
context, very similar to the BMD values of autogenous 
bone. Marx, et al.13 (2014) reported that BMD of 737 
HU was obtained after the reconstruction of critical 
defects with rh-BMP2, which is satisfactory for primary 
stabilization of dental implants. This indicates that BC 
is favorable, considering that BMD at 42 days in this 
study was 1554 H.
Previous studies that analyzed BC and inorganic 
bovine bone (Bio-Oss®) in surgeries to gain height 
in the maxillary sinus region or in the completion of 
post-exodontic alveoli show no statistically significant 
differences regarding the amount of mineralized bone 
between the tested biomaterials3,21. However, these 
studies did not verify the stability of dental implants 
after implantation, which is the main objective of oral 
rehabilitation. Frenken, et al.6 (2010) conducted a 
study to evaluate the quality and quantity of bone 
formed in the sinus floor elevation with BoneCeramic©, 
6 months post-surgery, showing that the vertical 
height achieved was maintained. The implants seemed 
osseointegrated even 3 months after repair. Therefore, 
further studies to investigate this situation should be 
performed, evaluating the stability of the implants at 
different times by resonance frequency analysis, since 
BC at 28 and 42 days in this study showed adequate 
BMD. Thus, filling the bone defect with BC showed 
long-term stability of the osseointegrated implant after 
installing the prosthesis.
In immunohistochemical results, osteoblast 
differentiation, indicated by RUNX-2 expression, 
showed low osteoblastic activity in CG at both time-
points (14 and 28 days), confirmed by histological 
analysis, in which the defects were filled by connective 
tissue with low presence of osteoblastic lineage cells. 
2018;26:e2016053110/12
Bone repair access of BoneCeramicTM in 5-mm defects: study on rat calvaria
J Appl Oral Sci.
In AG, this protein was moderately marked specially 
in osteocytes at 14 and 28 days, which underlines 
the longevity of bone autograft formation. Unlike 
the defects filled with BoneCeramic®, where the 
expression of RUNX-2 was decreased at 28 days, 
but was moderate at 14 days, and was still present 
after 28 days, even if lightly. Thus, although the 
osteoconductive potential of this material is known, 
we suggest that its presence within the bone defect 
may lead to an osteoblast differentiation response, as 
evidenced by the expression of RUNX-2 transcription 
factor. Miramond, et al.14 (2014) evaluated the 2-phase 
graft hydroxyapatite (HA)/tricalcium phosphate 
(TCP) in rat subcutaneous tissue and confirmed 
the osteoinductive potential of these biomaterials. 
Therefore, further studies should be conducted to 
quantify this protein through molecular analysis using 
real-time polymerase chain reaction (RT-PCR), to 
better understand these findings.
In a consequence for RUNX-2 labeling, and 
osteoblastic differentiation, OC labeling showed that 
newly formed bone mineralization after preparation of 
the bone defects was similar for the biomaterials used 
(AG and BCG), both at 14 and 28 days, indicated by 
moderate immunostaining of the OC protein. Defects 
left unfilled with particulate biomaterials (GC) had mild 
levels of this protein. Thus, OC, the most abundant 
non-collagen protein of the bone matrix, expressed 
during bone mineralization also represents marking 
cells of osteoblastic lineage, including osteoblasts and 
osteocytes, and it showed no difference in expression 
between the biomaterials tested. Thus, the comparison 
between BCG and CG, by OC expression, suggests 
that Ceramic Bone® was favorable for the filling of the 
defect created in rat calvaria.
Indirectly RUNX-2 and OC labeling representing 
the osteoblast activity give support to evaluate the 
osteoconduction property of the biomaterials filling the 
defect. In addition, angiogenesis after tissue damage, 
marked by VEGF protein expression, showed in this in 
vivo investigation that the blood supply, in particular 
to combat local oxygen deficit was moderate in both 
periods analyzed for the CG and BC groups. Particularly 
in BCG, the presence of VEGF characterizes its known 
osteoconductive potential. Since autologous bone 
already has viable cells for repair, including endothelial 
cells, VEGF was lightly immunostained at 14 days and 
the intensity increased at 28 days.
Osteoclast activity observed by TRAP expression 
demonstrated that autologous bone resorption 
decreased, whereas in BCG, resorption increased over 
time. This indicated that the biomaterial remained 
reabsorbed, and therefore delayed bone healing. 
Future studies with longer analysis time should be 
performed to investigate whether the reabsorption 
remains in this group, with more filling of the defect 
with mature bone.
Conclusion
Therefore, within the limits of this in vivo study, 
we may conclude that the tested biomaterial (BC) 
was favorable to fill bone defects until the end of the 
reporting period analyzed.
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